FilingSEC EDGAR8-K
Karyopharm Therapeutics Submits sNDA for Accelerated Approval of XPOVIO in Myelofibrosis
· SEC accepted
StagesNDA Submission
Filing content
Karyopharm Therapeutics has submitted a supplemental New Drug Application to the FDA seeking Accelerated Approval for XPOVIO in combination with ruxolitinib for patients with myelofibrosis.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…